(Q38059634)

28 August 2017

title

Systemic treatment of gastrointestinal cancer in elderly patients (English)

1 reference

28 August 2017

Silvana Leo

1

1 reference

28 August 2017

Caterina Accettura

2

1 reference

28 August 2017

Antonio Gnoni

3

1 reference

28 August 2017

Antonella Licchetta

4

1 reference

28 August 2017

Marianna Giampaglia

5

1 reference

28 August 2017

Annamaria Mauro

6

1 reference

28 August 2017

Valeria Saracino

7

1 reference

28 August 2017

Brian I Carr

8

1 reference

28 August 2017

publication date

1 March 2013

1 reference

Journal of gastrointestinal cancer

28 August 2017

published in

1 reference

28 August 2017

volume

44

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

22-32

1 reference

https://scigraph.springernature.com/pub.10.1007/s12029-012-9447-5

28 August 2017

exact match

0 references

cites work

Never too old? Age should not be a barrier to enrollment in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Geriatric oncology: an overview of progresses and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Geriatric oncology: challenges for the new century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

21 January 2018

Senior adult oncology

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuva

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Gastric cancer in the elderly: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Clinicopathological features of gastric carcinoma in younger and middle-aged patients: a comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Japanese Classification of Gastric Carcinoma - 2nd English Edition -

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Pathological characteristics of gastric carcinomas in the very old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

The outcome of surgical treatment for gastric carcinoma in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Chemotherapy in gastric cancer: a review and updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-012-9447-5

Evaluation of treatment strategies for gastric cancer in the elderly according to the number of abnormal parameters on preoperative examination

21 January 2018

1 reference

12 December 2020

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

1 reference

12 December 2020

Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study

1 reference

12 December 2020

Gastric resection in the aged (> or = 80 years) with gastric carcinoma: a multivariate analysis of prognostic factors

1 reference

12 December 2020

Effect of age on prognosis in patients with gastric cancer

1 reference

12 December 2020

Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Gastric cancer in the elderly: results of surgical treatment.

1 reference

12 December 2020

Impact of age on postoperative outcomes in 1118 gastric cancer patients undergoing surgical treatment

1 reference

12 December 2020

Chemotherapy for advanced gastric cancer

1 reference

12 December 2020

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

12 December 2020

Mortality for gastric cancer in elderly patients

1 reference

12 December 2020

The influence of age on resection rates and postoperative mortality in 2773 patients with gastric cancer

1 reference

12 December 2020

Chemotherapy in elderly patients with colorectal cancer

1 reference

12 December 2020

Surgical resection for gastric cancer in elderly patients: is there a difference in outcome?

1 reference

12 December 2020

Evaluation of surgical treatment for patients with gastric cancer who are over 80 years of age

1 reference

12 December 2020

The influence of age on the surgical management of carcinoma of the stomach

1 reference

12 December 2020

Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach

1 reference

12 December 2020

Effect of sex hormones on carcinogenesis in the stomachs of rats.

1 reference

12 December 2020

Clinicopathologic features of synchronous multifocal early gastric cancers.

1 reference

12 December 2020

10.1007/S12029-012-9447-5

Identifiers

DOI

1 reference

28 August 2017

1 reference